The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.

R. Razzaq,Domhnall O'Halloran,Colin G Beardwell,Stephen M Shalet

The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.

1993

R. Razzaq
Domhnall O'Halloran
Colin G Beardwell
Stephen M Shalet

CV205-502 is a new non-ergot dopamine agonist currently being studied for the treatment of hyperprolactinaemia. We have assessed the effects of CV205-502 on prolactin secretion and the clinical conseq

Keywords:

Hyperprolactinaemia
Bromocriptine
Endocrinology
Prolactin
Diabetes mellitus
Side effect
Internal medicine
Dopamine agonist
Chemotherapy
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations